LensOne Heads Toward Pivotal Trial

At Clinical Trials at the Summit 2026, Frank Brodie, MD, MBA, reviewed clinical findings for the prosthetic capsular bag and outlined plans for the GOLDEN GATE study.

By: Frank Brodie, MD, MBA, Diana V. Do, MD

Retinal Physician June 17, 2026

Objective:

To present findings on the prosthetic capsular bag (LensOne) and outline plans for the GOLDEN GATE study.

Approach:

Key Findings:

The prosthetic capsular bag shows better tilt and decentration than secondary lens techniques.
Results are comparable to in-the-bag phaco.

Interpretation:

Conclusion:

The GOLDEN GATE trial is set to further evaluate the prosthetic capsular bag's performance.

Frank Brodie

Medical Director for Vision and PRIMA

Affiliations: Science Corporation

Bio: Frank Brodie, MD, MBA, is medical director for vision and PRIMA at Science Corporation. His work described in Retinal Physician centers on the PRIMA subretinal photovoltaic implant system, a near-infrared–sensitive microarray being developed to restore central vision in patients with advanced geographic atrophy who have intact inner retinal layers. In discussing the PRIMA system, Dr. Brodie described the device’s subretinal photovoltaic design, wireless augmented-reality glasses interface, and intended stimulation of overlying bipolar cells as part of an approach to restoring the visual cascade in advanced retinal disease.

PentaVision